Comparative Pharmacology
Head-to-head clinical analysis: BRYNOVIN versus PIVYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRYNOVIN versus PIVYA.
BRYNOVIN vs PIVYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Pivya (pivmecillinam) is a prodrug of mecillinam, a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 2 (PBP2), leading to defective cell wall formation and cell death.
Adult: 150 mg orally twice daily.
1200 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 12 hours in patients with normal renal function; prolonged to 24-48 hours in moderate to severe renal impairment (CrCl < 30 mL/min).
Terminal elimination half-life of 3-4 hours in patients with normal renal function; may be prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion accounts for 70% of the administered dose as unchanged drug; biliary/fecal excretion accounts for 30%.
Primarily renal excretion as unchanged drug (approximately 70-80%); biliary/fecal excretion accounts for 10-15%.
Category C
Category C
Opioid Partial Agonist
Opioid Partial Agonist